S117: CHEMOTHERAPY-FREE TREATMENT WITH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB FOR OLDER ADULTS WITH NEWLY-DIAGNOSED, PH-NEGATIVE, CD22-POSITIVE, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: ALLIANCE A041703Matthew J. Wieduwilt, Richard M. Stone, Ken Byrd et al.|HemaSphere|2023Cited by 13
Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysisYannis K. Valtis, Karamjeet Sandhu, Rawan Faramand et al.|Blood|2025Cited by 2
Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Extended follow-up of alliance for clinical trials in oncology A041703 cohort 1 reveals durable remission and survivalMatthew J. Wieduwilt, Richard M. Stone, Jun Yin et al.|Blood|2025Cited by 2